The SHARP study investigates the potential of simvastatin, a widely used cholesterol-lowering medication, to reduce beta-amyloid levels and improve cerebral perfusion in adults at risk for Alzheimer's disease (AD). Given the increasing prevalence of AD and the lack of effective preventive therapies, successful outcomes could position simvastatin as a novel preventive treatment in the AD market. The study's findings may enhance the commercial viability of simvastatin beyond its current indications, potentially attracting interest from pharmaceutical companies focused on neurodegenerative diseases. Competitive implications include the need to monitor other AD-modifying therapies in development, particularly those targeting amyloid pathology. Diligence should focus on the regulatory landscape and potential market access challenges for repurposed drugs.